[HTML][HTML] Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease

AM Thawabteh, AW Ghanem, S AbuMadi, D Thaher… - Molecules, 2024 - mdpi.com
The most prevalent chronic neurodegenerative illness in the world is Alzheimer's disease
(AD). It results in mental symptoms including behavioral abnormalities and cognitive …

Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein

HM Mansour, AS El-Khatib - Ageing research reviews, 2023 - Elsevier
Parkinson's disease (PD) is a debilitating neurodegenerative disorder characterized by the
loss of dopaminergic neurons in the substania nigra (SN) and is associated with progressive …

Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms

HM Mansour, AF Mohamed, MM Khattab… - Food and Chemical …, 2023 - Elsevier
Parkinson's disease (PD) is characterized by motor impairments and progressive
dopaminergic neuronal death in the substantia nigra (SN). Recently, the involvement of …

The interference between SARS-COV-2 and Alzheimer's disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed …

HM Mansour - Ageing Research Reviews, 2024 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) has infected over 700 million people, with
up to 30% develo** neurological manifestations, including dementias. However, there is a …

Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor

HM Mansour, AF Mohamed, MM Khattab, AS El-Khatib - Brain Research, 2024 - Elsevier
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons
in the substantia nigra. The dopamine D3 receptor (D3R) plays a significant role in the …

Kinases and their derived inhibitors from natural products

TC Chiwoneso, Y Luo, Y Xu, X Chen, L Chen… - Bioorganic Chemistry, 2025 - Elsevier
Protein kinase dysregulation is a hallmark of many cancers, yet their tumorigenic
mechanisms remain elusive despite 60 years of study. Since learning that their mechanism …

Molecular targets for anticancer drug discovery and development

M Ntwasa, Z Dlamini - Frontiers in Genetics, 2024 - frontiersin.org
The advantages of molecularly targeted therapies are apparent and are the force behind the
fast-growing area of small molecule anticancer drug discovery and development. There is a …

[PDF][PDF] COMPARATIVE ANALYSIS OF SARACATINIB, NILOTINIB, AND DASATINIB BASED ON THEIR SAFETY, EFFICACY, AND TOLERABILITY IN TREATING …

DA Bheda, PD Pawar, A Rangaraju, A Rathod - 2024 - wjpr.s3.ap-south-1.amazonaws.com
WORLD JOURNAL OF PHARMACEUTICAL RESEARCH Page 1 www.wjpr.net │ Vol 13, Issue
23, 2024. │ ISO 9001: 2015 Certified Journal │ Bheda et al. World Journal of Pharmaceutical …